Pain Medication Taper Regimen Time frame to taper off 30-60 days



Similar documents
Benzodiazepines: A Model for Central Nervous System (CNS) Depressants

MEDICATION ABUSE IN OLDER ADULTS

Medical Malpractice Treatment Alprazolam benzodiazepine - A Case Study

Prescribing and Tapering Benzodiazepines

Assessment and Management of Opioid, Benzodiazepine, and Sedative-Hypnotic Withdrawal

Update on Buprenorphine: Induction and Ongoing Care

The CCB Science 2 Service Distance Learning Program

POST-TEST Pain Resource Professional Training Program University of Wisconsin Hospital & Clinics

Benzodiazepine Detoxification and Reduction of Long term Use

Review of Pharmacological Pain Management

ALCOHOL AND OTHER DRUG WITHDRAWAL: PRACTICE GUIDELINES

Alcohol Withdrawal Recognition and Treatment

PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain

Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients

Alcohol Withdrawal Syndromes

Opioids, Benzos, and Tapering, Oh My! Disclosures

1. According to recent US national estimates, which of the following substances is associated

MOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines

Treatment of Anxiety in the Methadone Maintained Patient

WITHDRAWAL OF ANALGESIA AND SEDATION

Opioid Treatment Services, Office-Based Opioid Treatment

Abstral Prescriber and Pharmacist Guide

Safely Discontinuing Opioid Analgesics

Alcohol Withdrawal. Introduction. Blood Alcohol Concentration. DSM-IV Criteria/Alcohol Abuse. Pharmacologic Effects of Alcohol

Information for Pharmacists

NEONATAL ABSTINENCE SYNDROME. Osama Naga, M.D. PGY2

Appendix to Tennessee Department of Health: Tennessee Clinical Practice Guidelines for Outpatient Management of Chronic Non- Malignant Pain

Dosing Guide. For Optimal Management of Opioid Dependence

COUNTY OF LOS ANGELES - DEPARTMENT OF MENTAL HEALTH OFFICE OF THE MEDICAL DIRECTOR. 3.4 PARAMETERS FOR THE USE OF ANXIOLYTIC MEDICATIONS October 2014

SAFE PAIN MEDICATION PRESCRIBING GUIDELINES

Treatment for Anxiety Disorders in Primary Care

Evidence Summary & References Guideline Development Process and Team... 12

OPIOIDS. Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School

Prescription Drug Addiction

Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy

New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery

Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone )

October We hope that our tool will be a useful aid in your efforts to improve pain management in your setting. Sincerely,

Outpatient Treatment of Alcohol Withdrawal. Daniel Duhigg, DO, MBA

General PROVIDER INITIALS: PHYSICIAN ORDERS

Clinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients

Philip Moore DO, Toxicology Fellow, PinnacleHealth Toxicology Center Joanne Konick-McMahan RN MSRN, Staff RN, PinnacleHealth

Non medical use of prescription medicines existing WHO advice

Prescription Drugs: Abuse and Addiction

Opioids Research to Practice

Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain (CNCP)

Genera&on O How did we get here? What can we do?

Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance

Alcohol and nicotine are widely abused substances and are often used together One study showed that 15% of patients visiting a primary care practice

Update on Treatment of the Dementias

Prevention and Treatment of Opioid and Benzodiazepine Withdrawal

Protecting your employees, physicians and you.

Naltrexone and Alcoholism Treatment Test

ALCOHOL DETOXIFICATION (IN-PATIENTS) PRESCRIBING GUIDELINE

Substance Use Learning Event Nov 3, 2015 Bill Bullock MD, CCFP

Downers/Depressants (pages 40-50)

How To Treat An Alcoholic Patient

Getting the best result from Opioid medicine. in the management of chronic pain

Bfrom anxiety disorders. Although physicians often prefer


Teen Misuse and Abuse of Alcohol and Prescription Drugs. Information for Parents

Conceptualizing and Integrating Medication Assistant Treatment into your Court s Armamentarium

Long Term Care Formulary HCD Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine)

GUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS

NALTREXONE INDUCED DETOXIFICATION FROM OPIOIDS A METHOD OF ANTAGONIST INITIATED TREATMENT

4/18/14. Background. Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients. Background. Signs and Symptoms of Withdrawal

Prior Authorization Guideline

Considerations when Using Controlled Substances to Treat Chronic Pain

Alcohol and Drug. A Cochrane Handbook. losief Abraha MD. Cristina Cusi MD. Regional Health Perugia

Management of benzodiazepine misuse

Guidelines for the use of unlicensed and off label medication within NHS Fife Addiction Services

Management of Patients with Narcotic Bowel Syndrome(1)

After seeing a patient on a Diversion Alert installment..

Use of Buprenorphine in the Treatment of Opioid Addiction

Discontinuation: Involuntary Discharge

Case. History of psoriatic arthritis, htn, essential tremor Meds: propranolol, etodolac, etanercept No history of prior psychiatric disease.

Opioid toxicity and alternative opioids. Palliative care fixed resource session

COMMUNITY BUPRENORPHINE PRESCRIBING IN OPIATE DEPENDENCE

Blueprint for Prescriber Continuing Education Program

Protecting your employees, the physicians and you. Opioid abuse is being talked about every day. Modern Medical has a solution.

PRESCRIPTION PAINKILLER OVERDOSES

GP Drug & Alcohol Supplement No.7 May 1997

This module reviews the following: Opioid addiction and the brain Descriptions and definitions of opioid agonists,

NICE Clinical guideline 23

Using Buprenorphine to Treat Acute Opioid Withdrawal in the ED

Symptom Based Alcohol Withdrawal Treatment

Triage, Assessment & Treatment Methadone 101/Hospitalist Workshop

Withdrawal Symptoms: How Long Do They Last?

Managing Patients with Pain, Psychiatric Co-Morbidity & Addiction

Care Management Council submission date: August Contact Information

Neurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011

Identifying Neonatal Abstinence Syndrome (NAS) and Treatment Guidelines University of Iowa Children s Hospital -2/11/13

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.

SCOTTISH PRISON SERVICE DRUG MISUSE AND DEPENDENCE OPERATIONAL GUIDANCE


VAADA Conference 2015 Benzodiazepines: Are they making your client s life hell?

Treatments for drug misuse

TREATING MAJOR DEPRESSIVE DISORDER

Withdrawal symptoms in long term sedation exposure of pediatric intensive care patients

Generalised anxiety disorder in adults

Transcription:

Pain Medication Taper Regimen Time frame to taper off 30-60 days Medication to taper Taper Regimen Comments Methadone Taper by no more than 25% Morphine Taper by no more than 25% Tramadol Taper by no more than 25% Hydrocodone/APAP Taper by no more than 25% Oxycodone Taper by no more than 25% Fentanyl Taper by no more than 25% Hydromorphone Taper by no more than 25% Methadone: For long-term users, see taper option below No Real taper needed but is a good adjunct or alternative when tapering Discontinuing long-term use of methadone may require a more gradual taper with a 5-10mg decrease per week until the patient is maintained on 20mg per day. At this point the taper should average 1-2mg reductions per day. For practical reasons, this may have to be done in 2.5mg increments due to product availability (examples in tables below). This part of the taper may require close patient monitoring, since the final 2 to 3 weeks of taper are most frequently associated with relapse. Methadone 14-Day Taper Dose(mg) # of 5mg Days Tablets 17.5 3.5 2 15 3 2 12.5 2.5 2 10 2 2 7.5 1.5 2 5 1 2 2.5 0.5 2 Methadone 21-Day Taper Dose(mg) # of 5mg Days Tablets 17.5 3.5 3 15 3 3 12.5 2.5 3 10 2 3 7.5 1.5 3 5 1 3 2.5 0.5 3

Adjunct Therapy Dosing Regimen Ibuprofen 400mg q 4-6hr prn Mild to moderate pain adult dose Naproxen 250-500 BID prn Mild to moderate pain adult APAP 325 to 650 mg every 4 to 6 Adult Dosage hours, or 1 g 3 to 4 times a day. Do not exceed 4 g/day Cycobenzaprine 5-10mg tid prn Adult dosage, For short periods of use up to 2-3 weeks Methocarbamol 500 mg tablets: initial: 3 tablets 4 times a day maintenance: 2 tablets 4 times a day. 750 mg tablets: initial: 2 tablets 4 times a day maintenance: 1 tablet every 4 hours, or 2 tablets 3 times a day. Adult dosage A dosage of 6 g/day is recommended for the first 48 to 72 hours of treatment.(for severe conditions 8 g/day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 g/day Clonidine 0.1mg 0.3mg BID Help with opioid withdrawl Methadone/opiate detoxification: 15 to 16 mcg/kg/day If tapering off a medication without switching to another pain medication (ie Methadone to Morphine) then taper by no more than 25%. If switching to another pain med you can be a little more aggressive because pt will not have withdrawal symptoms. Adjunct therapy can also be used, like NSAIDS, muscle relaxers, and clonidine 0.1mg- 0.3mg twice daily to help with opioid withdrawal.

Benzodiazepine Discontinuation Taper Recommendations for Outpatient Pharmacy Before a taper schedule can be initiated, several things must be considered Indication Depending on the disease state being treated, different approaches may need to be considered. For example, patients with panic disorder will probably require longer taper schedules (max 10% of the dose weekly). This can become difficult with product availability, but can certainly be accomplished with dose-rounding and creative scheduling. Most other indications may be responsive to a slightly more rapid taper (below) Specific benzodiazepines Alprazolam use may require longer taper schedules due to increased incidence of euphoria and more significant withdrawal symptoms compared to other benzodiazepines. The manufacturer recommends no more than a 0.5mg decrease every 3 days, and longer tapers for patients who don t tolerate this taper. Tapering should be an active process. Even the most gradual tapers should have pointed goals so that discontinuation remains a viable endpoint in the patient s mind. Too gradual of a taper may make the withdrawal symptoms a miserable focus-point in the patient s mind. The target time for discontinuation of the medication should be 8-12 weeks from the start of the taper. The more intense withdrawal symptoms tend to occur in the latter part of the taper schedule. Therefore the second half of the taper should take longer than the first half. Strategies Somewhat aggressive approach: the total dose of drug can be decreased by as much as 50% in the first two weeks, then 10% every week as tolerated. More conservative approach: taper by 10% every one or two weeks until 20% of original dose is reached, then taper by 5% every 2 to 4 weeks. Switching to longer acting benzodiazepines may allow for more rapid tapers and fewer side effects for patients taking high doses or prolonged (>3 months) use. Diazepam has been studied for this strategy. Switch to diazepam (multiply triazolam dose by 20, alprazolam dose by 10, and lorazepam dose by 5 to get the approximate equivalent dose of diazepam) then choose from the following o Decrease dose by 25% the first week, 25% the second week, then 12.5% every 7 days o Start with 50% of diazepam equivalent dose, then reduce by 10 to 20% daily o Decrease diazepam equivalent by 2mg every 1 to 2 weeks until half of initial dose reached, then by 1mg every 1 to 2 weeks.

Counseling Points Keep in mind that studies have shown that both anxiety and depression are often decreased after the taper has been completed for patients on long-term benzodiazepine therapy. Common withdrawal symptoms to be aware of include rebound anxiety, agitation, hallucinations seizures, tremor, sweating, and tachycardia. Since withdrawal symptoms can be fairly severe and have an abrupt onset (including seizures), the patient should not be driving or operating heavy machinery during the taper. Although these symptoms are very uncomfortable and disturbing, withdrawal from benzodiazepines alone is very rarely fatal. Adjunctive Therapy For anxiety and panic disorders, alternatives to benzodiazepines can be employed. SSRIs (1st line therapy for generalized anxiety disorder) should of course be considered if not in use already. Cognitive Behavioral Therapy has also been used successfully. Other options include: Carbamazapine (200-800mg/day) has been studies as adjunctive therapy to decrease the severity of benzodiazepine withdrawal as well as assist in keeping patients from needing benzodiazepine therapy in the future. Trials are limited, but evidence does support this adjunct therapy. Hydroxyzine has been shown to decrease severity of benzodiazepine withdrawal with a minimum of 50mg as a PRN dose Propranolol may be useful as a replacement for benzodiazepines for situational anxiety, but is not likely helpful for use during benzodiazepine withdrawal Buspirone has been shown definitively to not be helpful during a benzodiazepine taper and withdrawal, and is thus not recommended. It may maintain utility, however, as maintenance therapy for anxiety disorders after the benzodiazepine has been successfully discontinued.

References 1. American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. 2nd edition. January 2009. http://www.psychiatryonline.com/pracguide/practicepdfs/panicdisorder_2e_practicegu ideline.pdf. (Accessed January 10, 2012) 2. Benzodiazepine toolkit. Pharmacist s Letter/Prescriber s Letter 2011;27(4):270406 3. Chang F. Strategies for benzodiazepine withdrawal in seniors. CPJ 2005;138(8):38-40 4. Denis C, Fatseas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine monodependence management in outpatient settings (Review). Cochrane Database of Systematic Reviews. CD005194;2006(3) 5. Lader M, Tylee A, Donoghue J. Withdrawing Benzodiazepines in Primary Care. CNS Drugs 2009;23(1):19-34. 6. Rickels K, DeMartinis N, Rynn M, Mandos L. Pharmacologic Strategies for Discontinuing Benzodiazepine Treatment. J Clin Psychopharmacol 1999;19(6 Suppl 2):12S-16S. 7. Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2002;63 (Suppl 14):27-33.